{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T04:40:29Z","timestamp":1740112829748,"version":"3.37.3"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.intimp.2023.110581","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:34:03Z","timestamp":1688445243000},"page":"110581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mononuclear myeloid-derived suppressor cells expansion is associated with progression of liver failure in patients with acute decompensation of cirrhosis"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6323-5607","authenticated-orcid":false,"given":"Bingbing","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Change","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feidan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dexiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2023.110581_b0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"Asrani","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110581_b0010","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators., Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017, Lancet. 392 (2018) 1789-1858, doi: 10.1016\/S0140-6736(18)32279-7.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"10.1016\/j.intimp.2023.110581_b0015","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jhep.2021.01.002","article-title":"Pathophysiology of decompensated cirrhosis Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction","volume":"75","author":"Engelmann","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110581_b0020","doi-asserted-by":"crossref","unstructured":"G. D\u2019Amico, A. Morabito, M. D\u2019Amico, et al., Clinical states of cirrhosis and competing risks, J Hepatol. 68 (3) (2018) 563-576. doi:10.1016\/j.jhep.2017.10.020.","DOI":"10.1016\/j.jhep.2017.10.020"},{"issue":"11","key":"10.1016\/j.intimp.2023.110581_b0025","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2006.08.007","article-title":"Natural History of patients hospitalized for management of cirrhotic ascites","volume":"4","author":"Planas","year":"2006","journal-title":"Clin. Gastro Hepatol."},{"key":"10.1016\/j.intimp.2023.110581_b0030","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","article-title":"New clinical and pathophysiological perspectives defining the trajectory of cirrhosis","volume":"75","author":"Jalan","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110581_b0035","doi-asserted-by":"crossref","unstructured":"J. Trebicka, J. Fernandez, M. Papp, et al., PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis, J. Hepatol. 74 (2021) 1097\u20131108, doi:10.1016\/j.jhep.2020.11.019.","DOI":"10.1016\/j.jhep.2020.11.012"},{"key":"10.1016\/j.intimp.2023.110581_b0040","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2020.06.013","article-title":"The PREDICT study uncovers three clinical courses of acutely decompenstated cirrhosis that have distinct pathophysiology","volume":"73","author":"Trebicka","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.intimp.2023.110581_b0045","article-title":"Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis","volume":"4","author":"Wang","year":"2022","journal-title":"JHEP Rep."},{"key":"10.1016\/j.intimp.2023.110581_b0050","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat Commun."},{"key":"10.1016\/j.intimp.2023.110581_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00949","article-title":"Myeloid-derived suppressor cells: ductile targets in disease","volume":"10","author":"Consonni","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110581_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119627","article-title":"Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives","volume":"277","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2023.110581_b0065","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/1753425920961157","article-title":"Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodyplastic syndromes","volume":"26","author":"Han","year":"2020","journal-title":"Innate Immum."},{"key":"10.1016\/j.intimp.2023.110581_b0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2022.04.018","article-title":"Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1\/PD-L1 treatment efficacy","volume":"40","author":"Long","year":"2022","journal-title":"Cancer Cell."},{"key":"10.1016\/j.intimp.2023.110581_b0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10555-023-10079-1","article-title":"Role of myeloid-derived suppressor cells in tumor recurrence","volume":"42","author":"Cole","year":"2023","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.intimp.2023.110581_b0080","doi-asserted-by":"crossref","first-page":"6612477","DOI":"10.1155\/2021\/6612477","article-title":"The Relationship between Hepatic Myeloid-Derived Suppressor Cells and Clinicopathological Parameters in Patients with Chronic Liver Disease","volume":"2021","author":"Zhou","year":"2021","journal-title":"Biomed Res Int."},{"issue":"4","key":"10.1016\/j.intimp.2023.110581_b0085","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s10875-012-9861-2","article-title":"Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients","volume":"33","author":"Cai","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.intimp.2023.110581_b0090","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.4049\/jimmunol.1400849","article-title":"Myeloid-derived suppressor cells regulate immune response in patients with chronic hepatitis B virus infection through PD-1-induced IL-10","volume":"193","author":"Huang","year":"2014","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2023.110581_b0095","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1136\/gutjnl-2017-314184","article-title":"CD14+CD15-HLA-DR-myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure","volume":"67","author":"Bernsmeier","year":"2018","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2023.110581_b0100","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1111\/jcmm.14109","article-title":"Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease","volume":"23","author":"Gao","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110581_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","volume":"21","author":"Pallett","year":"2015","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2023.110581_b0110","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00262-016-1837-2","article-title":"Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma, Cancer Immunol","volume":"65","author":"Mizukoshi","year":"2016","journal-title":"Immunother"},{"key":"10.1016\/j.intimp.2023.110581_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100788","article-title":"Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis","volume":"28","author":"Deng","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.intimp.2023.110581_b0120","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet."},{"issue":"7","key":"10.1016\/j.intimp.2023.110581_b0125","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","article-title":"Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis","volume":"144","author":"Moreau","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2023.110581_b0130","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/ijc.28622","article-title":"Subpopulations of myeloid- derived suppressor cells impair T cell responses through independent nitric oxide- related pathways","volume":"134","author":"Raber","year":"2014","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.intimp.2023.110581_b0135","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2023.110581_b0140","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8 + T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2023.110581_b0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.110581_b0150","doi-asserted-by":"crossref","unstructured":"D.I. Gabrilovich, Myeloid-derived suppressor cells, Cancer Immunol. Res. 5 (2017) 3-8, doi: 10.1158\/2326-6066.CIR-16-0297.","DOI":"10.1158\/2326-6066.CIR-16-0297"},{"key":"10.1016\/j.intimp.2023.110581_b0155","doi-asserted-by":"crossref","unstructured":"L. Cassetta, K. Bruderek, J. Skrzeczynska-Moncznik,et al., Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation, J Immunother Cancer. 8 (2020) e001223. http:\/\/dx.doi.org\/10.1136\/jitc-2020-001223.","DOI":"10.1136\/jitc-2020-001223"},{"key":"10.1016\/j.intimp.2023.110581_b0160","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/cbin.11655","article-title":"Normalization in tumor ecosystem: opportunities and challenges","volume":"45","author":"Mortezaee","year":"2021","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.intimp.2023.110581_b0165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-17-0357","article-title":"Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals","volume":"24","author":"Shayan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110581_b0170","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3389\/fimmu.2019.01206","article-title":"The reversal of immune exclusion mediated by tadalafil and an anti-tumor vaccine also induces PDL1 upregulation in recurrent head and neck squamous cell carcinoma: interim analysis of a phase I clinical trial","volume":"10","author":"Weed","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110581_b0175","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med."},{"key":"10.1016\/j.intimp.2023.110581_b0180","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/2159-8290.CD-17-1203","article-title":"Pathobiological pseudohypoxia as a putative mechanism underlying myelodysplastic syndromes","volume":"8","author":"Hayashi","year":"2018","journal-title":"Cancer Discover."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923009074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T14:21:19Z","timestamp":1736432479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923009074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":36,"alternative-id":["S1567576923009074"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110581","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mononuclear myeloid-derived suppressor cells expansion is associated with progression of liver failure in patients with acute decompensation of cirrhosis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110581"}}